| Year |
Citation |
Score |
| 2023 |
Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, et al. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37678511 DOI: 10.1016/j.jtho.2023.08.034 |
0.399 |
|
| 2023 |
Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 41: 340-355.e6. PMID 36787696 DOI: 10.1016/j.ccell.2023.01.007 |
0.364 |
|
| 2023 |
Patel SA, Nilsson MB, Yang Y, Le X, Tran H, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, et al. IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36595561 DOI: 10.1158/1078-0432.CCR-22-3379 |
0.438 |
|
| 2022 |
Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, et al. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers. 14. PMID 35884533 DOI: 10.3390/cancers14143473 |
0.399 |
|
| 2022 |
Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, et al. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 40: 754-767.e6. PMID 35820397 DOI: 10.1016/j.ccell.2022.06.006 |
0.386 |
|
| 2022 |
Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Grigoryev DN, Selvan ME, Gümüş ZH, Tan Z, Zhang S, ... Nilsson M, et al. Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. Jco Precision Oncology. 1: 1-10. PMID 35172522 DOI: 10.1200/PO.17.00149 |
0.366 |
|
| 2021 |
Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, et al. Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Molecular Cancer Research : McR. PMID 34654720 DOI: 10.1158/1541-7786.MCR-21-0448 |
0.368 |
|
| 2021 |
Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. PMID 34526717 DOI: 10.1038/s41586-021-03898-1 |
0.342 |
|
| 2021 |
Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, et al. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. The Journal of Biological Chemistry. 101163. PMID 34481841 DOI: 10.1016/j.jbc.2021.101163 |
0.302 |
|
| 2021 |
Le X, Nilsson MB, Robichaux JP, Heymach JV. ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell. PMID 34388379 DOI: 10.1016/j.ccell.2021.07.017 |
0.44 |
|
| 2021 |
Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34311109 DOI: 10.1016/j.jtho.2021.07.007 |
0.41 |
|
| 2020 |
Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, et al. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33388477 DOI: 10.1016/j.jtho.2020.12.010 |
0.34 |
|
| 2020 |
Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, et al. Altered regulation of HIF-1α in naïve- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33309987 DOI: 10.1016/j.jtho.2020.11.022 |
0.423 |
|
| 2020 |
Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB. Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33096270 DOI: 10.1016/j.jtho.2020.10.006 |
0.447 |
|
| 2020 |
Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, et al. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 149: 33-40. PMID 32956986 DOI: 10.1016/J.Lungcan.2020.08.023 |
0.452 |
|
| 2020 |
Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine. 12. PMID 32878980 DOI: 10.1126/Scitranslmed.Aaz4589 |
0.485 |
|
| 2020 |
Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, et al. Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32540409 DOI: 10.1016/J.Jtho.2020.05.021 |
0.42 |
|
| 2020 |
Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 37: 420. PMID 32183953 DOI: 10.1016/J.Ccell.2020.03.003 |
0.365 |
|
| 2020 |
Patel SA, Nilsson M, Cho S, Le X, Heymach J. Abstract 5066: Investigating the role of IL-6 to modulate the immunosuppressive tumor microenvironment of EGFR mutant NSCLC Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5066 |
0.412 |
|
| 2020 |
Nilsson M, Sun H, Robichaux J, Diao L, Xi Y, Tong P, Sheng L, Hofstad M, Kawakami M, Le X, Liu X, Fang Y, Poteete A, Vailati Negrao M, Tran H, et al. IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components Journal of Thoracic Oncology. 15: S11. DOI: 10.1016/J.Jtho.2019.12.123 |
0.416 |
|
| 2020 |
Robichaux J, Elamin Y, Vijayan R, He J, Hu L, Zhang F, Poteete A, Pisegna M, Nilsson M, Sun H, Negrao M, Le X, Raymond V, Lanman R, Frampton G, et al. IA30 Investigating and Overcoming Primary Resistance of EGFR and HER2 (ERBB2) Exon 20 Mutant NSCLC Journal of Thoracic Oncology. 15: S9-S10. DOI: 10.1016/J.Jtho.2019.12.028 |
0.461 |
|
| 2019 |
Nilsson MB, Le X, Heymach JV. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. PMID 31828732 DOI: 10.1007/S11481-019-09891-W |
0.432 |
|
| 2019 |
Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Vailati Negrao M, Ahnert JR, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. PMID 31588020 DOI: 10.1016/J.Ccell.2019.09.001 |
0.481 |
|
| 2019 |
Robichaux JP, Nilsson MB, Zhang F, Hu L, He J, Pisegna M, Poteete A, Heymach JV. Abstract 347: Identification of poziotinib alone or in combination with TDM1 as a pan-HER2 inhibitor Cancer Research. 79: 347-347. DOI: 10.1158/1538-7445.Am2019-347 |
0.473 |
|
| 2019 |
Guijarro I, Poteete A, Cho S, Zhou T, Fan Y, Roarty E, Nilsson M, Parra E, Mino B, Wistuba I, Wang J, Skoulidis F, Heymach J. MA17.10 Lactate Transporter Blockade as a Strategy to Overcome VEGF Inhibitor-Resistance in LKB1-Deficient NSCLC Journal of Thoracic Oncology. 14: S320. DOI: 10.1016/J.Jtho.2019.08.644 |
0.404 |
|
| 2019 |
Elamin Y, Robichaux J, Carter B, Altan M, Gibbons D, Fossella F, Simon G, Lam V, Blumenschein G, Tsao A, Kurie J, Mott F, Negrao M, Hu L, He J, ... Nilsson M, et al. MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14: S282-S283. DOI: 10.1016/J.Jtho.2019.08.567 |
0.493 |
|
| 2019 |
Le X, Zhu V, Saltos A, Nikolinakos P, Mileham K, Velcheti V, Husain H, Nilsson M, Tran H, Roarty E, Kim E, Ou S, Sanborn R, Gray J, Wong K, et al. P2.14-24 An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC Journal of Thoracic Oncology. 14: S838. DOI: 10.1016/J.Jtho.2019.08.1809 |
0.394 |
|
| 2019 |
Robichaux J, Le X, Elamin Y, Nilsson M, Hu L, He J, Zhang F, Poteete A, Sun H, Rinsurongkawong W, Cross J, Heymach J. P1.14-08 Activity of Poziotinib and Other 2nd-Gen Quinazoline EGFR TKIs in Atypical Exon18 and Acquired Osimertinib Resistance Mutants Journal of Thoracic Oncology. 14: S555. DOI: 10.1016/J.Jtho.2019.08.1159 |
0.412 |
|
| 2018 |
Le X, Puri S, Negrao MV, Nilsson M, Robichaux JP, Boyle TA, Hicks JK, Lovinger K, Roarty EB, Rinsurongkawong W, Tang M, Sun H, Elamin YY, Lacerda L, Lewis J, et al. Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30228210 DOI: 10.1158/1078-0432.Ccr-18-1542 |
0.467 |
|
| 2018 |
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nature Medicine. PMID 29686424 DOI: 10.1038/S41591-018-0007-9 |
0.516 |
|
| 2018 |
Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, et al. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 9: 14268-14284. PMID 29581842 DOI: 10.18632/Oncotarget.24361 |
0.507 |
|
| 2018 |
Le X, Puri S, Negrao MV, Nilsson MB, Robichaux JP, Boyle TA, Hicks JK, Roarty E, Rinsurongkawong W, Glisson BS, Zhang J, Papadimitrakopoulou V, Gray JE, Heymach J. Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients. Journal of Clinical Oncology. 36: 9087-9087. DOI: 10.1200/Jco.2018.36.15_Suppl.9087 |
0.457 |
|
| 2018 |
Negrao MV, Reuben A, Robichaux JP, Le X, Nilsson MB, Wu C, Zhang J, Landry LC, Roarty E, Rinsurongkawong W, Swisher S, Simon GR, Futreal A, Glisson BS, Zhang J, et al. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. Journal of Clinical Oncology. 36: 9052-9052. DOI: 10.1200/Jco.2018.36.15_Suppl.9052 |
0.453 |
|
| 2018 |
Subbiah V, Cascone T, Hess KR, Subbiah IM, Nelson S, Morikawa N, Nilsson MB, Bhatt T, Ali S, William WN, Raymond VM, Lanman RB, Carbone DP, Salgia R, Owonikoko TK, et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. Journal of Clinical Oncology. 36: 9035-9035. DOI: 10.1200/Jco.2018.36.15_Suppl.9035 |
0.468 |
|
| 2018 |
Morikawa N, Nilsson MB, Guijarro I, Fan Y, Poteete A, Heymach JV. Abstract 4847: Evaluation of the combination of olaparib and cediranib in small-cell lung cancer cells Cancer Research. 78: 4847-4847. DOI: 10.1158/1538-7445.Am2018-4847 |
0.503 |
|
| 2018 |
Robichaux JP, Elamin YY, Tan Z, Negrao MV, Routbort M, Roeck B, Li S, Liu S, Chen T, Ahnert JR, Diao L, Nilsson MB, Zhang S, Yang Z, Wang J, et al. Abstract 4772: Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing Cancer Research. 78: 4772-4772. DOI: 10.1158/1538-7445.Am2018-4772 |
0.461 |
|
| 2018 |
Le X, Negrao MV, Nilsson M, Robichaux J, Roarty E, Rinsurongkawong W, Glisson B, Zhang J, Heymach JV. Abstract 2956: Mechanisms of resistance for osimertinib for patients with EGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance Cancer Research. 78: 2956-2956. DOI: 10.1158/1538-7445.Am2018-2956 |
0.464 |
|
| 2018 |
Hofstad ME, Gomez DR, Nilsson MB, Byers LA, Diao L, Wang J, Li L, Tong P, Heymach JV. Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B101 |
0.531 |
|
| 2018 |
Negrao M, Reuben A, Robichaux J, Le X, Nilsson M, Elamin Y, Wu C, Zhang J, Landry L, Roarty E, Rinsurongkawong W, Swisher S, Simon G, Futreal P, Glisson B, et al. P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S733-S734. DOI: 10.1016/J.Jtho.2018.08.1233 |
0.41 |
|
| 2017 |
Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, et al. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29313814 DOI: 10.1016/J.Jtho.2017.10.033 |
0.303 |
|
| 2017 |
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, et al. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Science Translational Medicine. 9. PMID 29118262 DOI: 10.1126/Scitranslmed.Aao4307 |
0.487 |
|
| 2017 |
Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells KJ, Haddad V, Hanrahan EO, Nilsson M, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, et al. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28559461 DOI: 10.1158/1078-0432.Ccr-16-3216 |
0.554 |
|
| 2017 |
Tsao AS, Wistuba II, Xia D, Byers LA, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Gumus ZH, Tan Z, Zhang S, Nilsson MB, Heymach J. Response of germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) to hedgehog inhibitor vismodegib. Journal of Clinical Oncology. 35: 9062-9062. DOI: 10.1200/Jco.2017.35.15_Suppl.9062 |
0.467 |
|
| 2017 |
Robichaux JP, Nilsson M, Heymach JV. Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants Cancer Research. 77: 2061-2061. DOI: 10.1158/1538-7445.Am2017-2061 |
0.496 |
|
| 2017 |
Elamin Y, Robichaux J, Lam V, Tsao A, Lu C, Blumenschein G, Kurie J, Brahmer J, Li S, Chen T, Estrada-Bernal A, Truini A, Nilsson M, Le A, Tan Z, et al. OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC Journal of Thoracic Oncology. 12: S1776. DOI: 10.1016/J.Jtho.2017.09.394 |
0.43 |
|
| 2017 |
Guijarro I, Poteete A, Fan Y, Cho S, Tong P, Roarty E, Nilsson M, Rodriguez-Canales J, Mino B, Cuentas EP, Wistuba I, Wang J, Heymach J. P3.03-027 LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models Journal of Thoracic Oncology. 12: S2283. DOI: 10.1016/J.Jtho.2017.09.1654 |
0.426 |
|
| 2017 |
Robichaux J, Tan Z, Nilsson M, Zhang S, Wong K, Heymach J. MA16.07 Drug Repurposing to Overcome De Novo Resistance of Non-Traditional EGFR Mutations Journal of Thoracic Oncology. 12: S438. DOI: 10.1016/J.Jtho.2016.11.511 |
0.39 |
|
| 2016 |
Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. PMID 27384992 DOI: 10.18632/Oncotarget.10332 |
0.54 |
|
| 2016 |
Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. Plos One. 11: e0152584. PMID 27055253 DOI: 10.1371/Journal.Pone.0152584 |
0.459 |
|
| 2016 |
Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J, trial TCEct. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. Journal of Clinical Oncology. 34: 9069-9069. DOI: 10.1200/Jco.2016.34.15_Suppl.9069 |
0.42 |
|
| 2016 |
Robichaux JP, Nilsson M, Fang B, Heymach JV. Abstract 4799: Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors Cancer Research. 76: 4799-4799. DOI: 10.1158/1538-7445.Am2016-4799 |
0.56 |
|
| 2016 |
Singh R, Wang Y, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Wang J, Heymach JV, Johnson FM. Abstract 4665: The combination of polo-like kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistancein vitroandin vivoin non-small cell lung cancer Cancer Research. 76: 4665-4665. DOI: 10.1158/1538-7445.Am2016-4665 |
0.552 |
|
| 2016 |
Nilsson MB, Sun H, Diao L, Tong P, Fan Y, Tran H, Liu D, Pena GA, Wang J, Rowe P, Webster A, Lee J, Gomez D, Hong WK, Wistuba I, et al. Abstract 4662: Beta blockers abrogate EGFR TKI resistance induced by adrenergic receptor-mediated upregulation of IL-6 and modulation of the LKB1/AMPK/mTOR axis Cancer Research. 76: 4662-4662. DOI: 10.1158/1538-7445.Am2016-4662 |
0.483 |
|
| 2016 |
Guijarro I, Poteete A, Yang C, Roarty E, Nilsson M, Sun H, Tong P, Chang E, Rodriguez-Canales J, Mino B, Parra E, Wistuba I, Wang J, Heffernan T, Heymach JV. Abstract 3272: LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC) Cancer Research. 76: 3272-3272. DOI: 10.1158/1538-7445.Am2016-3272 |
0.544 |
|
| 2016 |
Cardnell R, Tong P, Giri U, Gudikote J, Banerjee U, Kalu N, Fan Y, Nilsson M, Johnson F, Tran H, Wang J, Heymach J, Byers L. A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL European Journal of Cancer. 69: S82. DOI: 10.1016/S0959-8049(16)32840-4 |
0.335 |
|
| 2015 |
Nilsson M, Giri U, Gudikote J, Tang X, Lu W, Tran HT, Fan YH, Koo A, Diao L, Tong P, Wang J, Herbst RS, Johnson BE, Ryan AJ, Webster A, et al. KDR AMPLIFICATION IS ASSOCIATED WITH VEGF-INDUCED ACTIVATION OF mTOR AND INVASION PATHWAYS BUT DOES NOT PREDICT CLINICAL BENEFIT TO THE VEGFR TKI VANDETANIB. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26578684 DOI: 10.1158/1078-0432.Ccr-15-1994 |
0.494 |
|
| 2015 |
Ferrarotto R, Mitani Y, Cai Y, Diao L, Wang J, Nilsson MB, Glisson BS, Kies MS, William WN, Kupferman ME, Zweidler-McKay PA, Futreal A, El-Naggar AK, Heymach J. Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival. Journal of Clinical Oncology. 33: 6081-6081. DOI: 10.1200/Jco.2015.33.15_Suppl.6081 |
0.312 |
|
| 2015 |
Gudikote JP, Zhao H, Wang J, Fan Y, Diao L, Byers LA, Giri U, Nilsson M, Heymach JV. Abstract 2118: Nonsense-mediated decay regulates the expression of tumor suppressor transcripts and cancer pathways in non-small cell lung cancer cell lines Cancer Research. 75: 2118-2118. DOI: 10.1158/1538-7445.Am2015-2118 |
0.434 |
|
| 2014 |
Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3849-61. PMID 24850841 DOI: 10.1158/1078-0432.Ccr-13-1916 |
0.457 |
|
| 2014 |
Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy Cancer Research. 74: 2731-2741. PMID 24626092 DOI: 10.1158/0008-5472.Can-13-2044 |
0.423 |
|
| 2013 |
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 279-90. PMID 23091115 DOI: 10.1158/1078-0432.Ccr-12-1558 |
0.502 |
|
| 2013 |
Nilsson MB, Cascone T, Gudikote J, Roarty E, Diao L, Koo A, Ramachandran S, Riquelme E, Tran H, Wistuba I, Carbone DP, Heymach J. Abstract 374:KDRamplification in NSCLC is associated with sensitivity to VEGFR tyrosine kinase inhibitors. Cancer Research. 73: 374-374. DOI: 10.1158/1538-7445.Am2013-374 |
0.563 |
|
| 2012 |
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discovery. 2: 798-811. PMID 22961666 DOI: 10.1158/2159-8290.Cd-12-0112 |
0.47 |
|
| 2012 |
Byers LA, Nilsson MB, Masrorpour F, Wang J, Diao L, Bhardwaj V, Welsh J, Girard L, Coombes KR, Weinstein JN, Lippman SM, Glisson BS, Minna JD, Heymach J. Investigation of PARP1 as a therapeutic target in small cell lung cancer. Journal of Clinical Oncology. 30: 7096-7096. DOI: 10.1200/Jco.2012.30.15_Suppl.7096 |
0.467 |
|
| 2011 |
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Research. 71: 5512-21. PMID 21724587 DOI: 10.1158/0008-5472.Can-10-2614 |
0.483 |
|
| 2011 |
Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. The Journal of Clinical Investigation. 121: 1313-28. PMID 21436589 DOI: 10.1172/Jci42405 |
0.521 |
|
| 2011 |
Saigal B, Herynk MH, Cascone T, Nilsson M, Khajavi M, Saintigny P, Heymach JV. Abstract 3273: Estrogen contributes to bevacizumab resistance in xenograft models of non-small cell lung cancer (NSCLC) Cancer Research. 71: 3273-3273. DOI: 10.1158/1538-7445.Am2011-3273 |
0.369 |
|
| 2011 |
Cascone T, Saigal B, Reynolds DM, Erez B, Jacoby JJ, Nilsson MB, Lin HY, Herbst RS, Langley RR, Heymach JV. Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma Cancer Research. 71: 3269-3269. DOI: 10.1158/1538-7445.Am2011-3269 |
0.466 |
|
| 2010 |
Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer. 116: 2465-75. PMID 20225331 DOI: 10.1002/Cncr.25017 |
0.421 |
|
| 2010 |
Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 29: 2938-49. PMID 20208561 DOI: 10.1038/Onc.2010.60 |
0.339 |
|
| 2010 |
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 29: 2616-27. PMID 20154724 DOI: 10.1038/Onc.2010.16 |
0.537 |
|
| 2009 |
Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3484-94. PMID 19447865 DOI: 10.1158/1078-0432.Ccr-08-2904 |
0.532 |
|
| 2008 |
Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Molecular Cancer Therapeutics. 7: 418-24. PMID 18245671 DOI: 10.1158/1535-7163.Mct-07-0568 |
0.462 |
|
| 2007 |
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism Journal of Biological Chemistry. 282: 29919-29926. PMID 17716980 DOI: 10.1074/Jbc.M611539200 |
0.37 |
|
| 2006 |
Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4441s-4445s. PMID 16857825 DOI: 10.1158/1078-0432.Ccr-06-0286 |
0.509 |
|
| 2006 |
Nilsson M, Heymach JV. Vascular Endothelial Growth Factor (VEGF) Pathway Journal of Thoracic Oncology. 1: 768-770. DOI: 10.1016/S1556-0864(15)30404-4 |
0.334 |
|
| 2005 |
Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Research. 65: 10794-800. PMID 16322225 DOI: 10.1158/0008-5472.Can-05-0623 |
0.524 |
|
| 2005 |
Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, Gallick GE. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research. 65: 7214-22. PMID 16103072 DOI: 10.1158/0008-5472.Can-04-3858 |
0.421 |
|
| 2005 |
Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4923-33. PMID 16000591 DOI: 10.1158/1078-0432.Ccr-04-2060 |
0.551 |
|
| 2003 |
McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJ. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Research. 13: 379-87. PMID 12883364 DOI: 10.1097/00008390-200308000-00007 |
0.671 |
|
| 2003 |
Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Research. 63: 2971-6. PMID 12782605 |
0.486 |
|
| Show low-probability matches. |